IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 3904 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  »   My Preferences 
  »   Manuscript submission


This article has been cited by
1Sitagliptin relieves diabetic nephropathy fibrosis via the MAPK/ERK signaling pathway
Shufeng Cheng,Liang Li,Chunquan Song,Huijing Jin,Shouguo Ma,Ping Kang
Minerva Endocrinologica.2020;45(3)
2Activation of Spinal Glucagon-Like Peptide-1 Receptors Specifically Suppresses Pain Hypersensitivity
Nian Gong,Qi Xiao,Bin Zhu,Chang-Yue Zhang,Yan-Chao Wang,Hui Fan,Ai-Niu Ma,Yong-Xiang Wang
The Journal of Neuroscience.2014;34(15)5322
3Virtual Screening, Synthesis, and Biological Evaluation of Some Carbohydrazide Derivatives as Potential DPP-IV Inhibitors
Prerana B. Jadhav,Shailaja B. Jadhav,Mehrukh Zehravi,Mohammad S. Mubarak,Fahadul Islam,Philippe Jeandet,Sharuk L. Khan,Nazmul Hossain,Salma Rashid,Long Chiau Ming,Md. Moklesur Rahman Sarker,Mohd Fahami Nur Azlina
4Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
Masaya Sakamoto,Rimei Nishimura,Taiga Irako,Daisuke Tsujino,Kiyotaka Ando,Kazunori Utsunomiya
Cardiovascular Diabetology.2012;11(1)92
5HL-7 and HL-10 Peptides Stimulate Insulin Secretion in the INS-1 Insulinoma Cell Line through Incretin-Dependent Pathway and Increasing the Glucose Uptake in L6 Myoblast
Zahra Setayesh-Mehr,Mahdiye Poorsargol
International Journal of Peptide Research and Therapeutics.2021;27(4)2231
6Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice
P. Bansal,P. Paul,G. Shankar,D. Munjal,P.G. Nayak,K.I. Priyadarsini,M.K. Unnikrishnan
Biomedicine & Preventive Nutrition.2011;1(4)268
7Alkaloid Fraction of Litsea glutinosa Leaves Provides an Important Precursor for Inhibition of Dipeptidyl Peptidase 4 Activity
S W Kisnawaty,P Nityasewaka,B A R Sukma,A V Putrinadia,T Ma’rifah,D G Tamtomo,D Indarto
IOP Conference Series: Materials Science and Engineering.2019;546(6)062013
8Influence of the cellular environment on ligand binding kinetics at membrane-bound targets
Patrick M.L. Vanderheyden,Nerdjes Benachour
Bioorganic & Medicinal Chemistry Letters.2017;27(16)3621
9Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed mice
Andrew G. McCloskey,Michael G. Miskelly,Ryan A. Lafferty,Peter R. Flatt,Aine M McKillop
Biochemical Pharmacology.2023;208(16)115398
10Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
Simone E. Jaenisch,Catherine A. Abbott,Mark D. Gorrell,Peter Bampton,Ross N. Butler,Roger Yazbeck
Clinical and Translational Gastroenterology.2022;13(1)e00452
11Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
Shujaath Mehdi
Clinical and Translational Gastroenterology.2013;13(1)81
12Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis
A.G. McCloskey,M.G. Miskelly,P.R. Flatt,A.M. McKillop
European Journal of Pharmaceutical Sciences.2020;142(1)105104
13Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
Wolfgang Kothny,Valentina Lukashevich,James E. Foley,Marc S. Rendell,Anja Schweizer
14CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function
A.G. McCloskey,M.G. Miskelly,C.B.T. Moore,M.A. Nesbit,K.A. Christie,A.I. Owolabi,P.R. Flatt,A.M. McKillop
15Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
B. Ahrén,A. Schweizer,S. Dejager,E. B. Villhauer,B. E. Dunning,J. E. Foley
Diabetes, Obesity and Metabolism.2011;13(9)775
16Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222
Robert J. Greene,Hua Tu,John P. Gibbs,J. Greg Slatter
17Synthesis, Characterization and Screening of Some Novel 2-Methyl-N'- [(Z)-Substituted-Phenyl ethylidene] Imidazo [1, 2-a] Pyridine-3-Carbohy drazide Derivatives as DPP-IV Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Prerana A. Chavan,Shailaja B. Jadhav
Letters in Drug Design & Discovery.2022;19(2)160
18A novel self-sufficient biocatalyst based on transaminase and pyridoxal 5'-phosphate covalent co-immobilization and its application in continuous biosynthesis of sitagliptin
Xiao-Jian Zhang,Hao-Hao Fan,Nan Liu,Xin-Xin Wang,Feng Cheng,Zhi-Qiang Liu,Yu-Guo Zheng
Enzyme and Microbial Technology.2019;130(2)109362
19Stability of extemporaneously prepared sitagliptin phosphate solution
Abdel Naser Zaid,Yara Abu Zaaror,Aiman Kaddumi,Mashhour Ghanem,Nidal Jaradat,Tharaa Abu Salah,Sameera Siaj,Lana Omari,Girish Sailor
PLOS ONE.2022;17(3)e0262068
20The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease
Suncica Buljevic,Dijana Detel,Ester P. Pugel,Jadranka Varljen
Journal of Cellular Biochemistry.2018;119(8)6743
21Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan
Masato Odawara,Rieko Sagara
Journal of Diabetes & Metabolic Disorders.2015;15(1)6743
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow